Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,500 shares of NxStage Medical stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $14.00, for a total transaction of $21,000.00. Following the completion of the sale, the president now directly owns 124,447 shares of the company’s stock, valued at approximately $1,742,258. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NXTM has been the subject of a number of recent research reports. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $18.25.

NxStage Medical (NASDAQ:NXTM) opened at 13.76 on Friday. NxStage Medical has a one year low of $8.77 and a one year high of $15.65. The stock’s 50-day moving average is $13.7 and its 200-day moving average is $13.28. The company’s market cap is $847.7 million.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter last year, the company posted ($0.06) earnings per share. NxStage Medical’s revenue was up 13.3% compared to the same quarter last year. Analysts expect that NxStage Medical will post $-0.44 EPS for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Receive News & Ratings for NxStage Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.